LNCB 74
Alternative Names: B7-H4 targeting antibody drug conjugate - LegoChem/NextCure; LNCB-74Latest Information Update: 11 Apr 2024
At a glance
- Originator LegoChem Biosciences; NextCure
- Class Antibodies; Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Pyrroles
- Mechanism of Action DNA cross linking agents; DNA damage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Endometrial cancer; Ovarian cancer
- Research Cancer
Most Recent Events
- 08 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a preclinical trial in Solid tumours released by LegoChem Biosciences and NextCure
- 08 Apr 2024 LegoChem Biosciences and NextCure plans to initiate a clinical trial
- 05 Apr 2024 Pharmacodynamics and adverse event data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)